Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Satellos Bioscience Inc (MSCLF)

Satellos Bioscience Inc (MSCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 49,978
  • Shares Outstanding, K 112,792
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,770 K
  • 60-Month Beta 1.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.79
Trade MSCLF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings $-0.04 on 05/14/24
  • Next Earnings Date 06/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3321 +33.42%
on 06/11/24
0.5780 -23.34%
on 06/21/24
+0.0831 (+23.08%)
since 05/28/24
3-Month
0.2974 +48.99%
on 05/06/24
0.5780 -23.34%
on 06/21/24
+0.0687 (+18.35%)
since 03/28/24
52-Week
0.2205 +100.95%
on 11/10/23
0.5780 -23.34%
on 06/21/24
+0.0781 (+21.40%)
since 06/28/23

Most Recent Stories

More News
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Expands Leadership Team with New CFO Appointment

Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.Current CFO, Warren Whitehead, CPA,...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with DuchenneToronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Appointment of Chief Medical Officer

Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces Grant of Stock Options

Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

- $55 million equity financing closed- Resourced to advance lead drug candidate into clinical trialsToronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation...

MSCLF : 0.4431 (+8.98%)
MSCL.VN : 0.560 (+1.82%)

Business Summary

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience...

See More

Key Turning Points

3rd Resistance Point 0.4984
2nd Resistance Point 0.4708
1st Resistance Point 0.4569
Last Price 0.4431
1st Support Level 0.4154
2nd Support Level 0.3878
3rd Support Level 0.3739

See More

52-Week High 0.5780
Last Price 0.4431
Fibonacci 61.8% 0.4414
Fibonacci 50% 0.3993
Fibonacci 38.2% 0.3571
52-Week Low 0.2205

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar